• Special Issue Topic

    Innovative Therapeutics in Hepato-Gastroenterology

    Submission Deadline: December 31, 2024

    Guest Editor

    Prof. Amedeo Lonardo E-Mail

    Professor of Internal Medicine at the School of Specialization in Allergology and Clinical Immunology, University of Modena and Reggio Emilia, Italy

    Research Keywords:  NAFLD; NASH; MAFLD; gastroenterology; metabolic syndrome

    About the Special Issue

    Under-recognized but high rates of financial burden and psychological distress associated with increased health care utilization and poor health-related quality of life have been reported, particularly among patients with hepatic encephalopathy, ascites, liver cancer, hepatic failure, and liver transplantation recipients.

    Similarly, conditions affecting the GI tract, such as bleeding, cancer; gastroesophageal reflux disease; malabsorption; irritable bowel syndrome; functional dyspepsia; peptic ulcer disease; infectious colitis and enteritis; and inflammatory bowel disease are often associated with increasing healthcare expenditures resulting from complications which require frequent hospitalization, with expensive therapies being delivered as the standard of care in many areas.

    The burdening economics of many of the above conditions affecting the liver and the GI tract, therefore, calls for novel therapeutic approaches that may improve personalized clinical practice, patient life expectancy and quality of life.

    With the above backset, this Special Issue is specifically devoted to examining the rationale and cost-effectiveness ratio of standard of care approaches. It also explores areas of innovations spanning from lifestyle changes involving diet and physical exercise to drug treatment, gene therapy, surgical, endoscopic techniques, and interventional radiology to be delivered to patients with either hepatic diseases or conditions of the GI tract, both acute and chronic.

    Our Special Issue has no restrictions for contributors based on patient age (geriatrics, pediatrics, and adulthood) geographical area; drug treatment vs. lifestyle changes; endoscopic treatment; interventional ultrasonography and radiology; gene  therapy; surgery; medicinal chemistry; pharmaco-economics; phytopharmaceuticals and alternative medicine.  

    No publication charges will be sustained by Authors.  Each of the following types of articles are acceptable: NARRATIVE REVIEWS; MINI-REVIEWS; META-ANALYSIS; CASE REPORTS; ORIGINAL STUDIES (both basic science and clinical) pertaining to cancer and benign conditions affecting the liver, pancreas and gastrointestinal tract.


    Ufere NN, et al. Financial burden in adults with chronic liver disease: A scoping review. Liver Transpl. 2022 Dec;28(12):1920-1935. 

    Peery AF, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019 Jan;156(1):254-272.e11.

    Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011 Jul;17(7):1603-9.

    Keywords: pharmacotherapeutics; diet; gut microbiota; endoscopy; gene therapy; interventional radiology; personalized medicine; physical exercise; ultrasonography; surgery

    Call for Papers

    Published Articles

    Open Access
    Case Report
    Histological diagnosis of primary biliary cholangitis in one patient without cholestasis alterations: a case report that escaped guidelines
    Primary biliary cholangitis (PBC) is an autoimmune cholangiopathy that affects mainly women and, if untreated, can evolve into biliary cirrhosis. Its prevalence varies worldwide, depending on race,  [...] Read more.
    Matteo Biagi ... Pietro Andreone
    Published: January 22, 2024 Explor Drug Sci. 2024;2:1–5
    DOI: https://doi.org/10.37349/eds.2024.00033
    Times Cited: 0
    Open Access
    Case Report
    Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report
    Reactivation of hepatitis B virus (HBV; RHBV) is a significant concern during immunosuppressive therapy, as it can lead to severe hepatitis and liver failure. The article reports a case of RHBV duri [...] Read more.
    Elena Franchi ... Pietro Andreone
    Published: December 27, 2023 Explor Drug Sci. 2023;1:468–474
    DOI: https://doi.org/10.37349/eds.2023.00031
    Times Cited: 0
    Open Access
    Case Report
    Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure
    Thrombocytopenia is one of the most frequent implications of liver cirrhosis. This condition, when present in the severe form [platelet count (PLT) less than 50 × 109/L] correlates, with an increas [...] Read more.
    Davide Scalabrini ... Pietro Andreone
    Published: August 30, 2023 Explor Drug Sci. 2023;1:292–298
    DOI: https://doi.org/10.37349/eds.2023.00020
    Times Cited: 0
    Open Access
    Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes
    Nonalcoholic fatty liver disease (NAFLD), its more rapidly progressive steatohepatitic variant [nonalcoholic steatohepatitis, (NASH)], and the recently defined metabolic dysfunction-associated fatty [...] Read more.
    Amedeo Lonardo
    Published: August 28, 2023 Explor Drug Sci. 2023;1:239–252
    DOI: https://doi.org/10.37349/eds.2023.00016
    Times Cited: 0